Shares of Amgen Inc. AMGN rallied 1.13% to $290.33 Friday, on what proved to be an all-around great trading session for the ...

Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs to offset losses. Learn why AMGN ...

Novartis and Amgen also boast impeccable dividend track records, which should please investors. When broader equities are ...

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Patent claims reciting compounds where at least one group of a compound genus is defined by its function are common. For ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion ...

As President Trump touts his own executive orders to lower drug prices, the Medicare drug price negotiations begun during the Biden administration are continuing behind the scenes. Two companies – ...

The Puerto Rico Science, Technology and Research Trust and the National Institute for Innovation in Manufacturing ...

UBS may be able to carry out fewer share buy-backs in future following proposals that it should hold higher levels of core ...